
Pharmacally
Molgramostim
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Molgramostim
Clinical TrialsSavara Reports Gas-Transfer Gains with Molgramostim in aPAPA post-hoc analysis of the Phase 2/3 IMPALA trial found numerical improvements in gas transfer and CT-assessed lung abnormalities with inhaled molgramostim in patients with autoimmune pulmonary alveolar…Fact-Checked
Clinical TrialsSavara Reports New Phase 3 Biomarker Data Supporting Molgramostim in aPAPSavara presented new IMPALA-2 Phase 3 data at ATS 2026 showing that inhaled molgramostim improved pulmonary gas transfer and reduced key disease severity biomarkers in patients with autoimmune…Fact-Checked
Health TidingsMolgramostim Review Timeline Extended, FDA Seeks More Time on Savara’s BLAThe U.S. Food and Drug Administration has extended its review of Savara Inc.’s molgramostim BLA in autoimmune PAP by three months following a major amendment, with no concerns…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.